ArticleJournal of hematology & oncology2023

Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers.

Anja Seckinger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.